23 Feb 2026 | 3 Mins Read
Lupin gets EU nod for ranibizumab biosimilar
Flipitmoney
Lupin Ltd received European Commission approval for biosimilar ranibizumab, Ranluspec, used to treat age-related macular degeneration, diabetic retinopathy, and macular edema. Commercialization will be handled by Sandoz across the European Union (excluding Germany) and by Sandoz and Biogaran in France. Lupin shares rose 1.39% to ₹2,250.55.